MASH

Gyre Therapeutics Advances Fibrosis-First Pipeline with Strong Q3 Growth and Regulatory Momentum

Dateline — San Diego, California, November 7, 2025:Gyre Therapeutics, Inc. (NASDAQ: GYRE) reported Q3 2025 financial results and a...

By cGxPwire Editor
November 9, 2025

Bio-Pharma

Rivus Pharmaceuticals Reports Positive Phase 2 Results for HU6 in MASH Patients

CHARLOTTESVILLE, Va., and SOUTH SAN FRANCISCO, Calif., November 7, 2025 — Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company pioneering...

By cGxPwire Editor
November 7, 2025

M&A

Roche Completes Acquisition of 89bio in Strategic Biotech Expansion

Basel, Switzerland – October 30, 2025 — Roche Holding AG (SIX: RO, ROG; OTCQX: RHHBY) has successfully completed its...

By cGxPwire Editor
October 30, 2025

.Clinical

Sagimet Begins Phase 1 Trial of Denifanstat-Resmetirom Combo in MASH

SAN MATEO, Calif., Oct. 1, 2025 — Sagimet Biosciences announced that it has dosed the first participants in a...

By cGxPwire Editor
October 1, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

Gyre Therapeutics Advances Fibrosis-First Pipeline with Strong Q3 Growth and Regulatory Momentum

Rivus Pharmaceuticals Reports Positive Phase 2 Results for HU6 in MASH Patients

Roche Completes Acquisition of 89bio in Strategic Biotech Expansion

Sagimet Begins Phase 1 Trial of Denifanstat-Resmetirom Combo in MASH